

Implementation of a Non-Therapeutic Research Office at an NCI Designated Comprehensive Cancer Center



Todd Hoffert, BS, Alina Hoehn, MSHI, Xin Tang, PhD, MPH, Nina Naas, MPH, CPH
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Background

- Non-therapeutic research studies were historically managed by the study PI or the Clinical Trials Office (CTO) in a non-centralized fashion
- The Non-Therapeutic Research Office (NTR) was developed in October 2021 (fiscal year 2022) to provide centralized support for all non-treatment human subjects research at Moffitt
- NTR manages studies across multiple settings including Moffitt clinics, external clinics, and directly in the community
- Studies include investigator initiated and industry-sponsored studies.
- NTR grew rapidly over its first five years and continues to provide a cohesive model that is evolving with the business needs

Goals

- Compliant and robust processes aligned with institutional goals
- Centralize NTR in one office, reducing burden of non-therapeutic studies on the CTO
- Drive impactful science by providing research infrastructure
- Increase research quality while decreasing faculty burden
- Improve retention of staff
- Improve staff and faculty satisfaction

Outcomes

- NTR protocols contribute to all 5 CCSG programs (Fig. 1)
- Supports >700 studies (as of April 2026), an increase of 45% since inception
- Strong retention and growth³ of staff with >30% promotion rates FY23-FY25; 51% increase in FTEs since inception (Fig. 3)
- Decrease in activation times¹
- Reduction in feasibility review cycle time²

Figure 1. NTR Protocol Distribution by CCSG Program, N=708





Figure 2. # of Active NTR Protocols by Data Table 4 Report Type



Lessons Learned

- Centralized oversight of non-therapeutic research operations significantly reduces the burden on clinical teams while improving consistency, compliance, quality, and efficiency
- Investment in skilled, specialized staff drives both operational efficiency and high retention rates
- Growth in volume requires continuous evaluation and refinement of workflows, policies, and resource allocation
- Alignment with complementary research offices (e.g., CTO) is essential to avoid duplication and ensure seamless investigator experience
- Early and ongoing stakeholder engagement (faculty, leadership, departments) accelerates adoption and success of the model

Figure 3. NTR Staff Growth FY22-FY25

	Avg # Staff	% Increase Staff	# of Staff Promoted, (%)
End of FY 22	81	NA	13 (16.0%)
End of FY 23	95	17.2%	35 (36.8%)
End of FY 24	106	11.6%	39 (36.8%)
End of FY 25	122	15.1%	37 (30.3%)
Total Increase Average Staff			
FY 22 to FY 25	50.6%	NA	NA

Acknowledgments & References

We would like to acknowledge Dr. Erin Siegel, Dr. Shelley Tworoger, Dr. John Cleveland, Dr. Heather Jim, and Kristie Moffett for leading this effort and supporting the initial and continuing need for this infrastructure.

1. A.Hoehn, N.Naas (2025). *Implementing a Non-Therapeutic activation Team at a Comprehensive Cancer Center*. AACI CRI Annual Meeting. Chicago, IL
2. N.Naas, A.Hoehn (2025). *Implementing a Non-Therapeutic Feasibility Committee at a Comprehensive Cancer Center*. AACI CRI Annual Meeting Chicago, IL
3. L. Camperlengo (2025). *A Focus on Culture in Response to Rapid Growth: Moffitt Cancer Center's Non-Therapeutic Research Office (NTR)*. AACI CRI Annual Meeting Chicago, IL